Sarat Chandarlapaty

This paper develops a microfluidic tissue array platform for personalized drug screening using tumor explants or biopsies, showing reduced tumor cell viability and proliferative cell retention after treatment.

The paper maps CDK-drug interactions at single amino acid resolution using genome editing and computational analysis, identifying critical residues and resistance mechanisms.

This paper identifies eIF4A as a key regulator of ER translation in breast cancer and shows that inhibiting eIF4A, either alone or with fulvestrant, suppresses ER expression and tumor growth in advanced ER+ breast cancer.

This study identifies APOBEC3 mutagenesis as a common driver of therapy resistance in breast cancer, associated with poorer clinical outcomes.

This paper develops a multimodal transformer model using H&E images and text reports to predict recurrence scores in hormone receptor-positive breast cancer, achieving high accuracy and generalizability.

This study shows that carcinogen-induced DNA adducts enhance APOBEC3B-mediated mutagenesis, leading to increased mutation rates in cancer genomes.

The paper identifies how germline and somatic mutations interact to cause resistance to CDK4/6 inhibitors in breast cancer and proposes a sequential treatment strategy using PARP inhibitors.

The paper describes the development and clinical application of MSK-ACCESS, a liquid biopsy assay that improves the specificity of somatic variant detection in cell-free DNA by using paired normal sequencing.